R&D News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J pays $6.5bn for Momenta and its inflammatory disease hop...

Johnson & Johnson is to buy Momenta Pharmaceuticals for $6.5 billion, adding potential inflammatory diseases blockbuster nipocalimab to the pipeline at its Janssen pharmaceuticals unit.

News

Covid-19 Wearing mask in an airport departure lounge

Smell and taste loss could help identify COVID-19 at airport...

Smell and taste loss associated with COVID-19 differs from that experienced by patients with common colds or flu, according to researchers who said the symptom could be used to quickly iden

News

Analysts question Gilead's commitment to arthritis drug afte...

The FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage male fertility, prompting speculation that the big US pharma could be

News

Merck & Co plans £1bn hub in London's life sciences cluster

US pharmaceutical firm Merck & Co plans to build a £1 billion “hub” opposite London’s King’s Cross station, according to press reports.

News

Could AI avert a future coronavirus pandemic?

Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses?

News

Kiadis shares yo-yo on cell therapy trial for COVID-19

Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains o

J&J pays $6.5bn for Momenta and its inflammatory disease hop...

Smell and taste loss could help identify COVID-19 at airport...

Analysts question Gilead's commitment to arthritis drug afte...

Merck & Co plans £1bn hub in London's life sciences cluster

Could AI avert a future coronavirus pandemic?

Kiadis shares yo-yo on cell therapy trial for COVID-19

Novo Nordisk buoyed by outperforming oral Wegovy in Q1

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks